Skip to content
value.today

Ventas, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

P/EP/E of REIT - Healthcare Facilities: $2.4 B to $15.8 B, median $5.3 BPrice to salesPrice to sales of REIT - Healthcare Facilities: $16.0 B to $47.4 B, median $34.0 BPrice to bookPrice to book of REIT - Healthcare Facilities: $15.9 B to $31.3 B, median $27.6 B$0 M$12.8 B$25.6 B$38.4 B$51.2 BMarket value $46.2 B

Your own DCF model

A full discounted-cash-flow model of Ventas, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry REIT - Healthcare Facilities

Multiples of its companies with a market value at most 60 days old, times Ventas, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Ventas, Inc.Applied toValue (25th to 75th)Companies
P/E9.3× / 20.3× / 60.3×170.3×net income $262 M$2.4 B to $15.8 B10
Price to sales2.8× / 5.8× / 8.1×6.8×revenue $5.8 B$16.0 B to $47.4 B12
Price to book1.3× / 2.2× / 2.5×3.7×book equity $12.5 B$15.9 B to $31.3 B12

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Ventas, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

169.4×

Now above its median of 159.5×; range 41.8× to 349.9× over 25 months.

0×87×175×262×350×2020202120222023202420252026P/E 169×Median 159×

Price to sales

7.2×

Now above its median of 6.1×, in the top quarter of its range; range 4.7× to 7.8× over 30 months.

0×2×4×6×8×2020202120222023202420252026Price to sales 7×Median 6×

Price to book

3.7×

Now above its median of 2.9×, in the top quarter of its range; range 1.7× to 3.8× over 30 months.

0×1×2×3×4×2020202120222023202420252026Price to book 4×Median 3×

as of Oct 27, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 27, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$5.8 B$262 M$1.6 B$2.9 B$-1.3 B$12.3 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$4.9 B$88 M$1.3 B$2.5 B$-1.2 B$12.6 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$4.5 B$-30 M$1.1 B$649 M$470 M$13.0 BSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$4.1 B$-41 M$1.1 B$901 M$219 M$12.2 BSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$3.8 B$57 M$1.0 B$1.8 B$-776 M$11.9 BSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$3.8 B$441 M$1.5 B$607 M$843 M$11.5 BSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $46.2 B on Oct 27, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.